Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;49(7):6725-6739.
doi: 10.1007/s11033-022-07282-8. Epub 2022 Mar 11.

A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh

Golap Babu  1 , Shad Bin Islam  2 , Md Asaduzzaman Khan  3
Affiliations
Review

A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh

Golap Babu et al. Mol Biol Rep. 2022 Jul.

Abstract

Cancer is one of the major health burdens worldwide, and genetic polymorphisms in individuals are closely associated with cancer susceptibility. Like in many other developing countries, the risk of cancer is increasing among Bangladeshi population. Genetic polymorphisms in xenobiotic metabolic enzymes (CYP1A1, CYP2A6, CYP3A4, CYP3A5, NAT2, SULT1A), cell cycle regulatory proteins (TP53, HER2, MDM2, miR-218-2, TGFB), cell signaling protein (CDH1), DNA repair proteins (BRCA1, BRCA2, EXO1, RAD51, XRCC2, ECCR1, ERCC4, XPC, ERCC2), and others (HLA-DRB1, INSIG2, GCNT1P5) have been found to be associated with various cancers like cancers of breast, bladder, cervix, colon, lung, prostate, etc. in different studies with Bangladeshi population. In this review article, we have discussed these gene polymorphisms associated with cancers in the Bangladeshi population, and also made a comparison with other ethnic groups. This will probably be helpful in understanding drug effects, drug resistance, and personalized medicine in the population of this region.

Keywords: Bangladeshi population; Cancer susceptibility; Drug resistance; Genetic polymorphisms; Oncogenes; Tumor suppressors.

PubMed Disclaimer

References

    1. Sung H, Ferlay J, Siegel RL (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71 (3):209–249. doi: https://doi.org/10.3322/caac.21660
    1. Hussain SA, Sullivan R (2013) Cancer control in Bangladesh. Jpn J Clin Oncol 43(12):1159–1169. doi: https://doi.org/10.1093/jjco/hyt140 - DOI - PubMed - PMC
    1. Kou T, Kanai M, Matsumoto S, Okuno Y, Muto M (2016) The possibility of clinical sequencing in the management of cancer. Jpn J Clin Oncol 46(5):399–406. doi: https://doi.org/10.1093/jjco/hyw018 - DOI - PubMed
    1. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J, Kirkness EF, Denisov G, Lin Y, MacDonald JR, Pang AW, Shago M, Stockwell TB, Tsiamouri A, Bafna V, Bansal V, Kravitz SA, Busam DA, Beeson KY, McIntosh TC, Remington KA, Abril JF, Gill J, Borman J, Rogers YH, Frazier ME, Scherer SW, Strausberg RL, Venter JC (2007) The diploid genome sequence of an individual human. PLoS Biol 5(10):e254. doi: https://doi.org/10.1371/journal.pbio.0050254 - DOI - PubMed - PMC
    1. Mardis ER, Wilson RK (2009) Cancer genome sequencing: a review. Hum Mol Genet 18(R2):R163–168. doi: https://doi.org/10.1093/hmg/ddp396 - DOI - PubMed - PMC

LinkOut - more resources